Abstract
Aim
The present study aims to investigate the effects of betamethasone treatment on clinical outcome and laboratory data of pregnant women diagnosed with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome.
Methods
A prospective, randomized and placebo-controlled clinical trial was undertaken in a total of 60 pregnant women with HELLP syndrome who were treated at the perinatology department of the study center between January 2005 and February 2008. Betamethasone treatment (intramuscular injection of 12 mg in every 24 h) was given to 30 subjects while remaining 30 subjects received placebo. The treatment and control groups were compared in the aspects of clinical outcome and laboratory data.
Results
The alterations in platelet counts, alanine aminotransferase, aspartate aminotransferase and lactate dehydrogenase levels of women treated with betamethasone were statistically similar to those of the placebo group. Although there was a significant decrease in diastolic blood pressure values of control group (P = 0.04), alterations in systolic blood pressure values were statistically indifferent in both study groups. Hematological and metabolic complications occurred significantly less in women treated with betamethasone (P < 0.05). Interestingly, the percentage of women who received platelet transfusion was significantly higher in the control group (P < 0.005). No case of maternal mortality occurred.
Conclusions
The betamethasone treatment has ended up with insignificant alterations in clinical outcomes and laboratory data of women with HELLP syndrome except beneficial effects on metabolic complications and need for platelet transfusion. Further investigation is required to assess the efficiency of betamethasone in management of HELLP syndrome.
References
O’Brien JM, Milligan DA, Barton JR (2000) Impact of high-dose corticosteroid therapy for patients with HELLP syndrome. Am J Obstet Gynecol 183(4):921–924. doi:10.1067/mob.2000.108869
Riddell J 4th, Chenoweth CE, Kauffman CA (2004) Disseminated Scedosporium apiospermum infection in a previously healthy woman with HELLP syndrome. Mycoses 47(9–10):442–446. doi:10.1111/j.1439-0507.2004.01015.x
Magann EF, Martin JN Jr (1995) Complicated postpartum preeclampsia–eclampsia. Obstet Gynecol Clin North Am 22(2):337–356
Martin JN Jr, Thigpen BD, Rose CH, Cushman J, Moore A, May WL (2003) Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome. Am J Obstet Gynecol 189(3):830–834. doi:10.1067/S0002-9378(03)00763-4
Martin JN Jr, Magann EF, Isler CM (2003) HELLP syndrome: the scope of disease and treatment. Hypertens Pregnancy:141–188
Magann EF, Martin RW, Isaacs JD, Blake PG, Morrison JC, Martin JN Jr (1993) Corticosteroids for the enhancement of fetal lung maturity: impact on the gravida with preeclampsia and the HELLP syndrome. Aust N Z J Obstet Gynaecol 33:127–131. doi:10.1111/j.1479-828X.1993.tb02374.x
Magann EF, Bass DD, Chauhan SP, Sullivan DL, Martin RW, Martin JN Jr (1994) Antepartum corticosteroids: disease stabilization in patients with the syndrome of hemolysis, elevated liver enzymes and, low platelets (HELLP). Am J Obstet Gynecol 171:1148–1153
Magann EF, Perry KG Jr, Meydrech EF, Harris RL, Chauhan SP, Martin JN (1994) Postpartum corticosteroids: accelerated recovery from the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol 171:1154–1158
Vigil-De Gracia P, Garcia-Caceres E (1997) Dexamethasone in the post-partum treatment of HELLP syndrome. Int J Gynecol Obstet 59:217–221. 12
Martin JN Jr, Perry KG, Blake PG, May WA, Moore A, Robinette L (1997) Better maternal outcomes are achieved with dexamethasone therapy for postpartum HELLP syndrome. Am J Obstet Gynecol 177:1011–1017. doi:10.1016/S0002-9378(97)70005-X
Yalcin OT, Sener T, Hassa H, Ozalp S, Okur A (1998) Effects of postpartum corticosteroids in patients with HELLP syndrome. Int J Gynaecol Obstet 61:141–148. doi:10.1016/S0020-7292(98)00036-8
Varol F, Aydin T, Gucer F (2001) HELLP syndrome and postpartum corticosteroids. Int J Gynaecol Obstet 73:157–159. doi:10.1016/S0020-7292(00)00371-4
Isler CM, Magann EF, Rinehart BK, Terrone DA, Bass JD, Martin JN Jr (2003) Dexamethasone compared with betamethasone for glucocorticoid treatment of postpartum HELLP syndrome. Int J Gynaecol Obstet 80:291–297. doi:10.1016/S0020-7292(02)00394-6
Rose CH, Thigpen BD, Bofill JA, Cushman J, May WL, Martin JN Jr (2004) Obstetric implications of antepartum corticosteroid therapy for HELLP syndrome. Am J Obstet Gynecol 105(5):1011–1014
Fonseca JE, Méndez F, Cataño C, Arias F (2005) Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol 193:1591–1598. doi:10.1016/j.ajog.2005.07.037
Martin JN Jr, Rinehart BK, May WL, Magann EF, Terrone DA, Blake PG (1999) The spectrum of severe preeclampsia: comparative analysis by HELLP syndrome classification. Am J Obstet Gynecol 180:1373–1384. doi:10.1016/S0002-9378(99)70022-0
Tompkins JM, Thiagarajah S (1999) HELLP (hemolysis, elevated liver enzymes, and low platelet) syndrome: the benefit of corticosteroids. Am J Obstet Gynecol 181:304–309. doi:10.1016/S0002-9378(99)70552-1
O’Brien JM, Schumate SA, Satchwell SL, Milligan DA, Barton JR (2002) Maternal benefit of corticosteroid therapy in patients with HELLP syndrome: impact on rate of regional anesthesia. Am J Obstet Gynecol 186:475–479. doi:10.1067/mob.2002.121074
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ozer, A., Kanat-Pektas, M., Ozer, S. et al. The effects of betamethasone treatment on clinical and laboratory features of pregnant women with HELLP syndrome. Arch Gynecol Obstet 280, 65–70 (2009). https://doi.org/10.1007/s00404-008-0865-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-008-0865-3